{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:35:18Z","timestamp":1762673718729},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1007\/s11914-007-0013-1","type":"journal-article","created":{"date-parts":[[2009,4,25]],"date-time":"2009-04-25T02:05:36Z","timestamp":1240625136000},"page":"170-178","source":"Crossref","is-referenced-by-count":13,"title":["Bone loss in patients with breast or prostate cancer"],"prefix":"10.1007","volume":"5","author":[{"given":"Mimi I.","family":"Hu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Gagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilo","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,4,26]]},"reference":[{"key":"13_CR1","unstructured":"American Cancer Society: Cancer Facts & Figures 2007. Available at http:\/\/www.cancer.org\/downloads\/STT\/CAFF-2007PWSecured.pdf . Accessed June 2007."},{"key":"13_CR2","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","volume":"19","author":"C.L. Shapiro","year":"2001","unstructured":"Shapiro CL, Manola J, Leboff M: Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001, 19:3306\u20133311.","journal-title":"J Clin Oncol"},{"key":"13_CR3","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/sj.bjc.6690188","volume":"79","author":"J.A. Kanis","year":"1999","unstructured":"Kanis JA, McCloskey EV, Powles T, et al.: A high incidence of vertebral fracture in women with breast cancer. Br J Cancer 1999, 79:1179\u20131181.","journal-title":"Br J Cancer"},{"key":"13_CR4","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","volume":"165","author":"Z. Chen","year":"2005","unstructured":"Chen Z, Maricic M, Bassford TL, et al.: Fracture risk among breast cancer survivors: results from the Women\u2019s Health Initiative Observational Study. Arch Intern Med 2005, 165:552\u2013558.","journal-title":"Arch Intern Med"},{"key":"13_CR5","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1210\/jcem.87.8.8782","volume":"87","author":"D. Mittan","year":"2002","unstructured":"Mittan D, Lee S, Miller E, et al.: Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab 2002, 87:3656\u20133661.","journal-title":"J Clin Endocrinol Metab"},{"key":"13_CR6","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1097\/01.ju.0000059281.67667.97","volume":"169","author":"L.J. Melton","year":"2003","unstructured":"Melton LJ, Alothman KI, Khosla S, et al.: Fracture risk following bilateral orchiectomy. J Urol 2003, 169:1747\u20131750.","journal-title":"J Urol"},{"key":"13_CR7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1210\/er.2004-0001","volume":"26","author":"K. Janssens","year":"2005","unstructured":"Janssens K, ten Dijke P, Janssens S, Van Hul W: Transforming growth factor-beta1 to the bone. Endocr Rev 2005, 26:743\u2013774.","journal-title":"Endocr Rev"},{"key":"13_CR8","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1210\/endo.140.9.7131","volume":"140","author":"L.C. Hofbauer","year":"1999","unstructured":"Hofbauer LC, Khosla S, Dunstan CR, et al.: Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 1999, 140:4367\u20134370.","journal-title":"Endocrinology"},{"key":"13_CR9","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1210\/jc.2002-021429","volume":"88","author":"M. Benito","year":"2003","unstructured":"Benito M, Gomberg B, Wehrli FW, et al.: Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 2003, 88:1497\u20131502.","journal-title":"J Clin Endocrinol Metab"},{"key":"13_CR10","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1634\/theoncologist.11-10-1121","volume":"11","author":"T.A. Guise","year":"2006","unstructured":"Guise TA: Bone loss and fracture risk associated with cancer therapy. Oncologist 2006, 11:1121\u20131131.","journal-title":"Oncologist"},{"key":"13_CR11","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJM199811263392207","volume":"339","author":"C.K. Osborne","year":"1998","unstructured":"Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 1998, 339:1609\u20131618.","journal-title":"N Engl J Med"},{"key":"13_CR12","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","volume":"295","author":"V.G. Vogel","year":"2006","unstructured":"Vogel VG, Costantino JP, Wickerham DL, et al.: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006, 295:2727\u20132741.","journal-title":"JAMA"},{"key":"13_CR13","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1200\/JCO.2005.02.3515","volume":"24","author":"L. Vehmanen","year":"2006","unstructured":"Vehmanen L, Elomaa I, Blomqvist C, Saarto T: Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006, 24:675\u2013680.","journal-title":"J Clin Oncol"},{"key":"13_CR14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/028418698430007","volume":"37","author":"A. Resch","year":"1998","unstructured":"Resch A, Biber E, Siefert M, Resch H: Evidence that tamoxifen preserves bone density in late postmenopausal women with breast cancer. Acta Oncol 1998, 37:661\u2013664.","journal-title":"Acta Oncol"},{"key":"13_CR15","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","volume":"97","author":"B. Fisher","year":"2005","unstructured":"Fisher B, Costantino JP, Wickerham DL, et al.: Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 2005, 97:1652\u20131662.","journal-title":"J Natl Cancer Inst"},{"key":"13_CR16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(05)74803-0","volume":"365","author":"A. Howell","year":"2005","unstructured":"Howell A, Cuzick J, Baum M, et al.: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer. Lancet 2005, 365:60\u201362.","journal-title":"Lancet"},{"key":"13_CR17","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"A. Coates","year":"2007","unstructured":"Coates A, Keshaviah A, Thurlimann B, et al.: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398. J Clin Oncol 2007, 25:486\u2013492.","journal-title":"J Clin Oncol"},{"key":"13_CR18","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","volume":"369","author":"R.C. Coombes","year":"2007","unstructured":"Coombes RC, Kilbum LS, Snowdon CF, et al.: Survival and safety of exemestane versus tamoxifen after 2\u20133 years\u2019 tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559\u2013570.","journal-title":"Lancet"},{"key":"13_CR19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","volume":"23","author":"E.P. Winer","year":"2005","unstructured":"Winer EP, Hudis C, Burstein HJ, et al.: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619\u2013629.","journal-title":"J Clin Oncol"},{"key":"13_CR20","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","volume":"21","author":"R. Eastell","year":"2006","unstructured":"Eastell R, Hannon RA, Cuzick J, et al.: Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006, 21:1215\u20131223.","journal-title":"J Bone Miner Res"},{"key":"13_CR21","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1470-2045(06)70767-7","volume":"7","author":"A. Buzdar","year":"2006","unstructured":"The Arimidex, Tamoxifen, Alone or in Combination Trialists\u2019 Group, Buzdar A, Howell A, et al.: Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006, 7:633\u2013743.","journal-title":"Lancet Oncol"},{"key":"13_CR22","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1200\/JCO.2005.05.4882","volume":"24","author":"E.A. Perez","year":"2006","unstructured":"Perez EA, Josse RG, Pritchard KI, et al.: Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629\u20133635.","journal-title":"J Clin Oncol"},{"key":"13_CR23","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1158\/1078-0432.CCR-04-0438","volume":"10","author":"P.E. Goss","year":"2004","unstructured":"Goss PE, Qi S, Cheung AM, et al.: Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 2004, 10:5717\u20135723.","journal-title":"Clin Cancer Res"},{"key":"13_CR24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","volume":"8","author":"R.E. Coleman","year":"2007","unstructured":"Coleman RE, Banks LM, Girgis SI, et al.: Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007, 8:119\u2013127.","journal-title":"Lancet Oncol"},{"key":"13_CR25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/bcr979","volume":"7","author":"K. Pritchard","year":"2005","unstructured":"Pritchard K, Whelan T: Clinical trial update: National Cancer Institute of Canada. Breast Cancer Res 2005, 7:48\u201351.","journal-title":"Breast Cancer Res"},{"key":"13_CR26","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1200\/JCO.2004.08.148","volume":"22","author":"A. Sverrisdottir","year":"2004","unstructured":"Sverrisdottir A, Fornander T, Jacobsson H, et al.: Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J Clin Oncol 2004, 22:3694\u20133699.","journal-title":"J Clin Oncol"},{"key":"13_CR27","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","volume":"14","author":"J. Bines","year":"1996","unstructured":"Bines J, Oleske DM, Cobleigh MA: Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996, 14:1718\u20131729.","journal-title":"J Clin Oncol"},{"key":"13_CR28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3109\/07357909809039747","volume":"16","author":"J.A. Headley","year":"1998","unstructured":"Headley JA, Theriault RL, LeBlanc AD, et al.: Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest 1998, 16:6\u201311.","journal-title":"Cancer Invest"},{"key":"13_CR29","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0360-3016(92)90895-O","volume":"23","author":"S.M. Pierce","year":"1992","unstructured":"Pierce SM, Recht A, Lingos TI, et al.: Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer. Int J Radiat Oncol Biol Phys 1992, 23:915\u2013923.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"13_CR30","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1210\/en.2006-0459","volume":"147","author":"D. Jia","year":"2006","unstructured":"Jia D, O\u2019Brien CA, Stewart SA, et al.: Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006, 147:5592\u20135599.","journal-title":"Endocrinology"},{"key":"13_CR31","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1001\/jama.281.16.1505","volume":"281","author":"M.S. LeBoff","year":"1999","unstructured":"LeBoff MS, Kohlmeier L, Hurwitz S, et al.: Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999, 281:1505\u20131511.","journal-title":"JAMA"},{"key":"13_CR32","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM199212033272305","volume":"327","author":"M.C. Chapuy","year":"1992","unstructured":"Chapuy MC, Arlot ME, Duboeuf F, et al.: Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992, 327:1637\u20131642.","journal-title":"N Engl J Med"},{"key":"13_CR33","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","volume":"21","author":"B.E. Hillner","year":"2003","unstructured":"Hillner BE, Ingle JN, Chlebowski RT, et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042\u20134057.","journal-title":"J Clin Oncol"},{"key":"13_CR34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1023\/B:BREA.0000041624.00665.4e","volume":"87","author":"L. Vehmanen","year":"2004","unstructured":"Vehmanen L, Saarto T, Risteli J, et al.: Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure. Breast Cancer Res Treat 2004, 87:181\u2013188.","journal-title":"Breast Cancer Res Treat"},{"key":"13_CR35","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.2004-1444","volume":"90","author":"G.H. Fuleihan","year":"2005","unstructured":"Fuleihan GH, Salamoun M, Mourad YA, et al.: Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 2005, 90:3209\u20133214.","journal-title":"J Clin Endocrinol Metab"},{"key":"13_CR36","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","volume":"15","author":"T. Saarto","year":"1997","unstructured":"Saarto T, Blomqvist C, Valimaki M, et al.: Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997, 15:1341\u20131347.","journal-title":"J Clin Oncol"},{"key":"13_CR37","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","volume":"90","author":"T.J. Powles","year":"1998","unstructured":"Powles TJ, McCloskey E, Paterson AH, et al.: Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 1998, 90:704\u2013708.","journal-title":"J Natl Cancer Inst"},{"key":"13_CR38","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","volume":"15","author":"P.D. Delmas","year":"1997","unstructured":"Delmas PD, Balena R, Confravreaux E, et al.: Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997, 15:955\u2013962.","journal-title":"J Clin Oncol"},{"key":"13_CR39","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1210\/jc.2006-1272","volume":"92","author":"S.L. Greenspan","year":"2007","unstructured":"Greenspan SL, Bhattacharya RK, Seeika SM, et al.: Prevention of bone loss in survivors of breast cancer: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 2007, 92:131\u2013136.","journal-title":"J Clin Endocrinol Metab"},{"key":"13_CR40","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","volume":"25","author":"M.F. Gnant","year":"2007","unstructured":"Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al.: Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820\u2013828.","journal-title":"J Clin Oncol"},{"key":"13_CR41","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00298427","volume":"57","author":"S. Eriksson","year":"1995","unstructured":"Eriksson S, Eriksson A, Stege R, Carlstr\u00f6m K: Bone mineral density in patients with prostatic cancer treated with orchiectomy and with estrogens. Calcif Tissue Int 1995, 57:97\u201399.","journal-title":"Calcif Tissue Int"},{"key":"13_CR42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0022-5347(01)65165-6","volume":"157","author":"H.W. Daniell","year":"1997","unstructured":"Daniell HW: Osteoporosis after orchiectomy for prostate cancer. J Urol 1997, 157:439\u2013444.","journal-title":"J Urol"},{"key":"13_CR43","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/1097-0142(20010615)91:12<2238::AID-CNCR1254>3.0.CO;2-2","volume":"91","author":"M.R. Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Fallon MA, et al.: Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer 2001, 91:2238\u20132245.","journal-title":"Cancer"},{"key":"13_CR44","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","volume":"100","author":"T.H. Diamond","year":"2004","unstructured":"Diamond TH, Higano CS, Smith MR, et al.: Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004, 100:892\u2013899.","journal-title":"Cancer"},{"key":"13_CR45","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0022-5347(01)61639-2","volume":"161","author":"J.F. Maillefert","year":"1999","unstructured":"Maillefert JF, Sibilia J, Michel F, et al.: Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 1999, 161:1219\u20131222.","journal-title":"J Urol"},{"key":"13_CR46","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0022-5347(05)64561-2","volume":"168","author":"M.G. Oefelein","year":"2002","unstructured":"Oefelein MG, Ricchiuti V, Conrad W, Resnick MI: Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002, 168:1005\u20131007.","journal-title":"J Urol"},{"key":"13_CR47","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","volume":"345","author":"M.R. Smith","year":"2001","unstructured":"Smith MR, McGovern FJ, Zietman AL, et al.: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001, 345:948\u2013955.","journal-title":"N Engl J Med"},{"key":"13_CR48","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","volume":"169","author":"M.R. Smith","year":"2003","unstructured":"Smith MR, Eastham J, Gleason DM, et al.: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003, 169:2008\u20132012.","journal-title":"J Urol"},{"key":"13_CR49","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","volume":"146","author":"S.L. Greenspan","year":"2007","unstructured":"Greenspan SL, Nelson JB, Trump DL, Resnick NM: Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med 2007, 146:416\u2013424.","journal-title":"Ann Intern Med"},{"key":"13_CR50","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1210\/jc.2003-032058","volume":"89","author":"M.R. Smith","year":"2004","unstructured":"Smith MR, Fallon MA, Lee H, Finkelstein JS: Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab 2004, 89:3841\u20133846.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-007-0013-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-007-0013-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-007-0013-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:33:43Z","timestamp":1559421223000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-007-0013-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["13"],"URL":"https:\/\/doi.org\/10.1007\/s11914-007-0013-1","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}